RGNX — Regenxbio Inc · rev $114.4M

Regenxbio Inc (RGNX) is a biotechnology company listed on US.

Latest reported RGNX revenue for 2026-06-30 was $114.4M. Net income was -$67.3M. RGNX currently screens at market cap $440.4M.

Use this RGNX page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the RGNX quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the RGNX SEC filings page. Lician reads the product cache first so this HTML stays unique to Regenxbio Inc even when a live quote feed is slow.

Regenxbio Inc latest statements (FY2025)

Latest cached year on this hub. Full RGNX income, balance, and cash tables.

  • Revenue$170.4M
  • Net Income-$193.9M
  • Total Assets$453.0M
  • Total Debt$0
  • Free Cash Flow-$126.4M

RGNX recent filings